Conversation with The Cancer Letter

Conversation with The Cancer Letter

Hyman: “This approval adds to the growing utility of sequencing in patients with cancer”
Conversation with The Cancer Letter

Hyman: “This approval adds to the growing utility of sequencing in patients with cancer”

As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval.
By Paul Goldberg
Ramirez: We no longer offer minimally invasive radical hysterectomy at MD Anderson
Conversation with The Cancer LetterFree

Ramirez: We no longer offer minimally invasive radical hysterectomy at MD Anderson

When cervical cancer patients were referred to MD Anderson Cancer Center for a prospective, phase III trial testing for noninferiority of minimally invasive vs. open abdominal radical hysterectomy, many requested the minimally invasive approach, because their referring physicians said it was better, said Pedro Ramirez, a professor of gynecologic oncology at MD Anderson.
By Matthew Bin Han Ong